Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and
middle‐aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and …

The skin barrier is broadly composed of two elements—a physical barrier mostly localised in
the epidermis, and an immune barrier localised in both the dermis and epidermis. These two …

Importance Determining psoriasis prevalence is fundamental to understanding the burden of
the disease, the populations most affected, and health policies to address the disease …

Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease
with a great impact on healthcare systems worldwide. As targeted therapies have …

Importance Psoriasis is a common autoinflammatory disease influenced by complex
interactions between environmental and genetic factors. The influence of long-term air …

Introduction Previous studies have proposed a possible gut–skin axis, and linked gut
microbiota to psoriasis risks. However, there is heterogeneity in existing evidence …

Psoriasis is a chronic, autoimmune skin disease affecting about 2–4% of the worldwide
population. It is now perceived as a systemic disease because of the complex pathogenesis …

Introduction The long-term benefit–risk profiles of licensed and investigational treatments for
moderate-to-severe plaque psoriasis have not been fully characterized. Methods …

Psoriasis is a chronic inflammatory disease characterized by squamous and erythematous
plaques on the skin and the involvement of the immune system. Global prevalence for …

Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to
the difficulty of objectively quantifying the disease's severity, considering the limitations of …